InMode Ltd INMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025
-
InMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
-
InMode Confirms Receipt of Unsolicited Proposal
-
Securities Fraud Investigation Into InMode Ltd. (INMD) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
-
InMode Ltd. (INMD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
-
Securities Fraud Investigation Into InMode Ltd. (INMD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
-
InMode Confirms Receipt of Unsolicited Proposal
-
InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer
Trading Information
- Previous Close Price
- $15.21
- Day Range
- $15.06–15.29
- 52-Week Range
- $12.72–16.74
- Bid/Ask
- $15.00 / $15.30
- Shares Outstanding
- 57.48M
- Market Cap
- $869.11M
- Volume/Avg
- 1,374 / 827,344
Key Statistics
- Price/Earnings (Normalized)
- 10.17
- Price/Sales
- 2.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 10.10%
Company Profile
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 660
- Website
- https://www.inmodemd.com
Valuation
|
Metric
|
INMD
|
|---|---|
Price/Earnings (Normalized) | 10.17 |
Price/Book Value | 1.38 |
Price/Sales | 2.54 |
Price/Cash Flow | 9.82 |
Price/Earnings
INMD
Financial Strength
|
Metric
|
INMD
|
|---|---|
Quick Ratio | 7.28 |
Current Ratio | 8.18 |
Interest Coverage | — |
Quick Ratio
INMD
Profitability
|
Metric
|
INMD
|
|---|---|
Return on Assets (Normalized) | 11.87% |
Return on Equity (Normalized) | 13.42% |
Return on Invested Capital (Normalized) | 10.48% |
Return on Assets
INMD
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|l^l?%^t | LOCK|Hn?FD | $187B | |||
| Stryker Corp
SYK
| LOCK|q!!ybh> | LOCK|v?r | $129B | |||
| Medtronic PLC
MDT
| LOCK|&?p&?< | LOCK|l<$W | $110B | |||
| Boston Scientific Corp
BSX
| LOCK|#dQ>@r | LOCK|dS@q | $71B | |||
| Edwards Lifesciences Corp
EW
| LOCK|<TKct!x | LOCK|VN!w | $51B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|B>&^dhj | LOCK|gxz | $32B | |||
| DexCom Inc
DXCM
| LOCK|V?!@zS?j | LOCK|!%>FX | $31B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|j?f | LOCK|@mt | $26B | |||
| Steris PLC
STE
| LOCK|dx<tf#W | LOCK|>Y^jf | $23B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|@p<Pj<p | LOCK|$l | $19B |
United States